Glenmark Generics Ltd's US subsidiary (GGI) has notified that the company has started distribution of Morphine Sulfate Oral Concentrate Solution in the U.S. market through a licensing pact with a U.S. based pharmaceutical development company. 

The latest introduction will be the fifth product offered by Glenmark in the segment of pain management.

The company will market Morphine Sulfate Oral Concentrate Solution in three presentations, which is indicative for the relief of severe acute and severe chronic pain.

Glenmark Generics Ltd, a division of drug maker Glenmark Pharmaceuticals Ltd, has made announcement about the launching of its anti-hypertension drug ‘Perindopril’ in the UK market.

Lawyers for drug maker Wyeth and the Bush administration told the U.S. Supreme Court that according to a federal law pharmaceutical companies are not liable for harm from medicines that meet the standards set by the Food and Drug Administration and used as the label indicates.

Caraco Pharmaceutical Laboratories, the Detroit-based generic subsidiary of Sun Pharmaceuticals Ltd., has been issued a letter of warning by the US Food and Drug Administration (FDA), and all its future marketing approvals for medicines have been withheld due to some quality-control issues.

This action of the US regulator comes in the wake of certain technical inadequacies identified by it during a May 2008 inspection. The FDA considered some of its observations to be repeat observations, and hence issued the warning letter.

Caraco said the FDA observations include, among other things, the inadequate and untimely investigation by the quality control unit of certain incidents at the facility contrary to the company’s standard operating procedures.

Caraco Pharmaceutical Laboratories, the Detroit-based generic subsidiary of Sun Pharmaceuticals Ltd., has been issued a letter of warning by the US Food and Drug Administration (FDA), and all its future marketing approvals for medicines have been withheld due to some quality-control issues.

This action of the US regulator comes in the wake of certain technical inadequacies identified by it during a May 2008 inspection. The FDA considered some of its observations to be repeat observations, and hence issued the warning letter.